Alkermes Announces Initiation Of Vibrance-3 Phase 2 Study Evaluating Alks 2680 For The Treatment Of Idiopathic Hypersomnia
Reuters
04-01
April 1 (Reuters) - Alkermes Plc :: *ALKERMES ANNOUNCES INITIATION OF VIBRANCE-3 PHASE 2 STUDY EVALUATING ALKS 2680 FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA